普美显在肝硬化结节多步癌变及肝细胞癌早期诊断中的应用

Clinical application of liver- specific contrast agent Gd^+- EOB- DTPA in progression assessment and early diagnosis of hepatocellular carcinoma

普美显是一种肝细胞特异性对比剂,同时具有细胞内及细胞外功能,能被具有正常功能的肝细胞所摄取并排泄入胆道,其比例约为50%。回顾及总结了近2年来在本院放射科所做的普美显增强磁共振检查病例,重点研究了该对比剂对于早期或小肝细胞癌的检出、肝细胞癌分级的潜能及肝细胞癌多步癌变中肝硬化结节良恶性的鉴别这三方面,从而得出普美显对于肝细胞癌诊断的有效性及其独特优势,为临床肝细胞癌患者提供更为全面的信息。

Gd^ ＋ - EOB - DTPA, a liver - specific contrast agent for magnetic resonance imaging （ MRI）, has intracellular and extracellular functions. The contrast agent can be absorbed into normal liver cells and excreted into the bile, with an absorption rate of about 50% and an excretion rate of about 50%. The author reviews and summarizes the cases who underwent Gd^ ＋ - EOB - DTPA - enhanced MRI in the De-partment of Radiology, Zhongshan Hospital in recent two years and focuses on the use of this contrast agent in following aspects ： detection of early or small hepatocellular carcinoma （HCC） , potential value for HCC grading, and differentiation between benign and malignant cirrhotic nodules in the multi - step progression of HCC. This review shows the effectiveness and unique advantage of Gd^ ＋ - EOB - DTPA in the di-agnosis of HCC, providing more comprehensive information for HCC patients.